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ABSTRACT
Streptococcus agalactiae, or group B Streptococcus (GBS), infects diverse hosts including humans
and economically important species such as cattle and fishes. In the context of human health, GBS
is a major cause of neonatal infections and an emerging cause of invasive disease in adults and of
foodborne disease in Southeast Asia. Here we show that GBS is able to establish a systemic
infection in Galleria mellonella larvae that is associated with extensive bacterial replication and
dose-dependent larval survival. This infection model is suitable for use with GBS isolates from
both homeothermic and poikilothermic hosts. Hypervirulent sequence types (ST) associated with
invasive human disease in neonates (ST17) or adults (ST283) show increased virulence in this
model, indicating it may be useful in studying GBS virulence determinants, albeit with limitations
for some host-specific virulence factors. In addition, we demonstrate that larval survival can be
afforded by antibiotic treatment and so the model may also be useful in the development of
novel anti-GBS strategies. The use of G. mellonella in GBS research has the potential to provide
a low-cost infection model that could reduce the number of vertebrates used in the study of GBS
infection.
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Introduction
Streptococcus agalactiae, or group B Streptococcus
(GBS) is a Gram-positive multi-host pathogen and
a major cause of human neonatal infections and mor-
tality. GBS was initially described in 1887 as an animal
pathogen responsible for mastitis in ruminants and
although largely eradicated in some countries with
a highly developed dairy industry, remains a major
cause of bovine mastitis in many countries [1]. In
1966, GBS infection of fish was reported in the USA
[2] with subsequent outbreaks described in fish farms
in Asia and the Americas [3,4] and, most recently, in
Africa [5]. GBS infection is often associated with high
levels of mortality in fish and with the worldwide
growth of aquaculture has a significant economic
impact [6]. In the 1970s GBS was described as the
leading cause of human neonatal infectious morbidity
and mortality with two distinct GBS-associated syn-
dromes: early-onset disease occurring 0–6 days after
birth and late-onset disease occurring 7 days–3 months
after birth [7,8]. Sequence type (ST) 17 is the most
common strain affecting neonates and is recognized
as a hypervirulent clone [9,10]. The implementation
of routine antibiotic prophylaxis during labor in many
countries has resulted in a decrease of the incidence of
early-onset disease, but the number of cases of late-
onset disease has remained stable or even increased in
some countries [8,11]. In other countries, routine anti-
biotic prophylaxis is not recommended, in part because
of concern about the potential impact on the infant
microbiome [12]. GBS is also recognized as an emer-
ging pathogen in adults that is associated with high
fatality rates, reaching 15% in high-income countries
[13–15]. Adult GBS infections are often associated with
underlying co-morbidities, but a recent foodborne out-
break of invasive ST283 GBS disease in Singapore was
linked to the consumption of raw fish and occurred in
previously healthy adults [16,17]. Despite some level of
host adaptation, e.g. association of ST17 with human
neonatal infectious disease [10], ST67 with cattle [18]
and association of ST7, ST283 and clonal complex (CC)
552 with poikilothermic animals [19], host-association
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is not absolute and interspecies transmission between
people, cattle and fish may occur [16,20,21].
The routine use of antibiotic prophylaxis in pregnant
women carrying GBS in many countries and routine
use of antimicrobials in aquaculture and dairy farming
may all exert selective pressure that favors the emer-
gence of antimicrobial resistance (AMR) in GBS [22].
The first line of treatment against GBS infections in
humans and cattle is beta-lactams antibiotics, such as
penicillin, to which GBS strains were considered uni-
versally susceptible. Since 1994, cases of reduced peni-
cillin susceptibility caused by mutations in Penicillin-
Binding Protein 1a (PBP1a), PBP2b and PBP2x have
been described in GBS from humans [23–25] and cattle
[26]. In cases of penicillin allergy, macrolides and lin-
cosamides, such as erythromycin and clindamycin, are
considered to be the best alternative. Reported resis-
tance to erythromycin ranges from just over 14% in
South America [27] to around 30% in North America
and Europe [28,29] and over 70% in China [30]. To
limit the risk of disease and reduce reliance on anti-
microbials for GBS control, vaccine development is an
active area of research in humans [31,32] and fishes [6]
and to a lesser extent in cattle [33]. Currently, there is
no GBS vaccine commercially available for human or
bovine use and commercially available fish vaccines do
not provide cross-protection to all relevant serotypes.
Consequently, the development of alternative anti-GBS
strategies is of prime importance [34].
A number of in vivo models exists for GBS infection
(mice, rats, zebrafish) and are valuable for the study of
host–pathogen interactions and virulence [35–37]. In
addition, challenge studies with GBS are conducted in
the target host species, notably cattle and tilapia, rather
than in model species [31,38]. To reduce the use of
vertebrate animals in scientific research, larvae of the
greater wax moth (Galleria mellonella) are increasingly
being used as an alternate infection model for several
human and non-human bacterial pathogens such as
Pseudomonas aeruginosa [39], Bacillus cereus [40],
Listeria monocytogenes [41,42], Vibrio anguillarum
[43] and Clostridium difficile [44]. They have also
been used to study the virulence of Streptococcus spp.,
notably Streptococcus pyogenes [45,46], Streptococcus
pneumonia [47], and Streptococcus suis [48]. Their
ease of use, short life span, and cost-effectiveness
make them a useful tool for screening of new antimi-
crobials and pathogen mutant libraries [49,50]. The
genome of Galleria mellonella has recently been
sequenced [51] and transcriptome and microRNA
data from larvae are available [52,53], further increas-
ing the appeal of the model. While the larvae rely
entirely on the innate immune system and do not
possess an adaptive immune system, their innate
immune system has remarkable similarities in terms
of function to the innate immune system of vertebrates
[49,54]. Indeed, phagocytosis in insects and mammals
is believed to be similar, with the hemolymph of larvae
containing phagocytic immune cells called hemocytes
similar to neutrophils found in blood. Additionally,
bacterial infection results in the production of antimi-
crobial peptides (AMPs) by the insect fat body, the
equivalent of the mammalian liver, and an increase of
reactive oxygen species generation [55–57].
Here, we evaluate the use of Galleria mellonella
larvae as an in vivo model of infection for GBS by
testing their susceptibility to human, bovine or fish
GBS isolates encompassing host-associated and multi-
host STs. We also determine the utility of G. mellonella
larvae for in vivo screening of antimicrobial efficacy
during GBS infection to explore its potential use in
the evaluation of new antibacterial treatments.
Results
G. mellonella larvae are susceptible to GBS
infection
To begin to assess the suitability of G. mellonella larvae
as an infection model for GBS isolated from its major
hosts, we tested the susceptibility of larvae to dose-
dependent killing by GBS from human, bovine and
piscine origin. Larvae were challenged with serial dilu-
tions of two STs that are hypervirulent in humans, i.e.
ST17 and ST283, represented by isolates of ST17
(human MRI Z2-093 and bovine MRI Z1-363) and
one isolate of ST283 (piscine STIR-CD-25). Infected
larvae were incubated at 37°C and survival were mon-
itored at 18 h, 24 h, and 48 h postinfection (represen-
tative example in Figure 1(A-C), additional replicates in
Figure S1(A-C)). All isolates induced a dose-dependent
response that was reproducible for each isolate in three
independent experiments. Immunohistochemical ana-
lysis of infected larvae with an anti-GBS antibody indi-
cated extensive bacterial replication within larvae
during the course of infection, particularly in the fat
body and the tissue surrounding the digestive tract
(Figure 1(D)). To generate quantitative data on the
extent of GBS replication, CFU counts from homoge-
nized infected larvae were measured for the piscine
ST283 isolate STIR-CD-25 (Figure 1(E)). CFU counts
show extensive growth of ST283 up to 8
h postinfection, which is followed by a stationary phase.
To further asses the utility of this model across
a range of GBS strains, we tested the susceptibility of
larvae to the fish-specific ST260 isolate STIR-CD-10.
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Unlike piscine isolates of ST7 or ST283, which belong
to clonal complexes that also affect humans, ST260
belongs to clonal complex 552, which is only found in
cold-blooded animals, and grows optimally at 28°C.
Similar to experiments with non-ST260 strains at 37°
C, ST260 (piscine isolate STIR-CD-10) displayed dose-
Figure 1. Virulence and replication of group B Streptococcus (GBS) in the Galleria mellonella larvae model.
Kaplan–Meier survival curves of larvae challenged with serial dilutions of ST17 bovine isolate MRI Z1-363 (A), ST17 human isolate MRI
Z2-093 (B), ST283 fish isolate STIR-CD-25 (C). All survival curves show one representative experiment, with use of 10 larvae/group.
PBS-injected larvae were used as a negative control, and all survived until the endpoint of the experiment. (D) Immunohistochemical
analysis shows extensive GBS replication in G. melonella. Larvae were inoculated with 106 CFU of MRI Z2-366 (ST283) and collected
immediately after inoculation and 6 h and 12 h postchallenge. GBS was detected through immunohistochemical staining of sections.
For histological examination, sections were stained with hematoxylin and eosin. Scale bar 500 µM. Abbreviations: DT, digestive tract;
FB, fat body; T, trachea. Red arrows indicate the presence of GBS, visible based on brown staining, and blue arrows indicate
phagocytic cells. (E) Bacterial counts of homogenized larvae, from two distinct experiments using 3 larvae per time point, showing
in vivo growth of GBS ST283 isolate STIR-CD-25 in G. mellonella larvae following infection with 106 CFUs. Errors bars represent the
standard deviation (SD).
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dependent killing of G. mellonella larvae at 28°C
(Figure 2(A), Figure S1(D)). To determine if incubation
temperature is a critical parameter in determining the
course of infection as has been previously described for
a Galleria model of Streptococcus pyogenes [45], one
ST283 isolate (piscine MRI Z2-366) was used to chal-
lenge larvae at both 28°C and 37°C. Percentage survival
24 h and 48 h postinfection was similar at both tem-
peratures, suggesting that the temperature of incuba-
tion post-challenge does not greatly influence virulence
of GBS in this model (Figure 2(B)).
Strains associated with hypervirulence in humans
show increased virulence in G. melonella
Next, we examined if isolates from different host spe-
cies showed different levels of virulence in G. melonella
larvae through the determination of the LD50 for GBS
isolates of human (n = 9), bovine (n = 12) and piscine
origin (n = 13). For each host species, we selected
isolates representing major epidemiologically relevant
capsular serotypes and clonal complexes, including
those that are found across multiple host species
(Table S1). LD50 values for all isolates following infec-
tion of larvae at 37°C are shown in Table S1. Overall,
LD50 values of human and bovine isolates were rela-
tively homogenous with values ranging from 4.9 × 105
to 3.2 × 106 CFU and 1.1 × 106 to 4.5 × 106 CFU,
respectively. Interestingly, LD50 values obtained for
infection with fish isolates at 37°C showed a wider
range (from 2.4 × 104 to 1.1 × 107 CFU) and were
significantly lower than those of human and bovine
isolates, indicating that fish isolates are more virulent
in the Galleria model (Figure 3(A)). This apparent
host-effect was largely driven by ST283, as ST283 iso-
lates were more virulent than non-ST283 isolates from
Figure 2. Virulence of group B Streptococcus (GBS) in the Galleria mellonella infection model is largely temperature independent.
(A) Kaplan–Meier survival curves of larvae challenged with serial dilutions of ST-260 fish isolate STIR-CD-10 demonstrating dose-dependent
survival at 28°C. Survival curves show one representative experiment, with use of 10 larvae per group. PBS-injected larvae were used as
a negative control, and all survived until the endpoint of the experiment. (B) Survival of larvae at 24 h and 48 h postinfection by ST283 fish
isolate (MRI Z2-366, 9.105 CFU/mL) with incubation at 37°C or 28°C. Data were collected from two distinct experiments with 10 larvae per
group for each experiment, errors bars represent the SD (ns: not significant; unpaired t-test).
Figure 3. Group B Streptococcus (GBS) strains associated with hypervirulence in humans show increased virulence in Galleria mellonella.
LD50 values determined by Probit analysis following infection of larvae by (A) Streptococcus agalactiae human (red), fish (blue) and bovine
(green) isolates at 28°C (ST260 fish isolates, square symbols) or 37°C (non-ST260 isolates, round symbols), by (B) fish ST283 and non-ST283
isolates and by (C) human (red) and bovine (green) ST17 and non-ST17 isolates. Each datapoint represents the mean LD50 of at least two
experiments in which groups of 10 larvae were infected with 4 different inoculums, errors bars represent the SD (**: p < 0.01; ***: p <
0.001; Mann–Whitney test).
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fish (Figure 3(B)). Within the non-piscine isolates,
ST17 isolates showed the highest virulence, with the
comparison of LD50 between ST17 and non-ST17
groups showing a small but significant difference
(Figure 3(C)). There was no significant correlation
between capsular serotype and virulence (Figure S2).
Antibiotic treatment rescues larvae infected with
susceptible strains
To test the utility of the Galleria model to screen for
antibiotic efficacy against GBS infection in vivo we
tested the ability of erythromycin, ampicillin, and tetra-
cycline to afford survival against a lethal GBS infection.
Because of the wide range of LD50 values observed for
fish isolates, one representative for each ST from fish
isolates (ST7, ST283, ST500, ST260) was included. For
human isolates, a hypervirulent and a non-
hypervirulent ST were selected (ST17, ST8), whilst
bovine isolates were selected to match STs from fish-
or human-derived isolates if available (ST8, ST7, and
ST17). One ST260 fish isolate (STIR-CD-10) was tested
by challenging the larvae and incubating at 28°C post-
infection with the other isolates tested at 37°C. Prior to
infection studies, the MIC of each isolate to
erythromycin, ampicillin, and tetracycline was deter-
mined by the broth dilution method (Table S1). All
isolates tested are susceptible to erythromycin and
ampicillin with MICs ranging from 0.031 to 0.5 µg/
ml. One fish (ST283; STIR-CD-25), two human
(ST17; MRI Z2-093 and ST8; MRI Z2-137), and two
bovine (ST8; MRI Z2-053 and ST7; MRI Z1-354) iso-
lates were found to be resistant to tetracycline (MIC
ranging from 16 to 64 µg/ml) while the other tested
isolates are susceptible (MICs ranging from 0.125 to 1
µg/ml). Except for those isolates identified as resistant
to tetracycline, one injection of 20 µg of erythromycin,
ampicillin or tetracycline 2 hpost infection, was able to
rescue larvae infected by fish, human or bovine isolates
(Figure 4(A-C)). For those isolates resistant to tetracy-
cline survival of Galleria was not significantly different
on tetracycline treatment from control larvae treated
with PBS after challenge. These data indicate an excel-
lent correlation between GBS sensitivity to antibiotics
in vitro and in vivo at both 37°C and 28°C, indicating
this model may be useful for testing novel anti-GBS
agents. To further characterize the use of the Galleria
infection model for drug-screening assay, groups of
larvae infected with an ST283 fish isolate were treated
with increasing concentration of ampicillin, showing
Figure 4. Antibiotic treatment affords survival of Galleria mellonella larvae against a lethal dose of group B Streptococcus (GBS).
(A-C) Survival of treated (injection of 10 µL of 2 mg/mL erythromycin, ampicillin or tetracycline 2 hours post-infection) and untreated (10
µL of sterile PBS) larvae 48 hours post infection with GBS fish (A), human (B) or bovine (C) isolates. R indicates that the isolate is resistant to
the corresponding antibiotic. Data was collected from at least 2 distinct experiments with 10 larvae per group for each experiment and
error bars represent the SD (ns: non significant, *: p < 0.05, **: p < 0.01; ***: p < 0.001; one-way ANOVA). (D) Kaplan-Meier survival curves of
larvae challenged with 9.106 CFUs of ST-283 fish isolate STIR-CD-25 demonstrating dose-dependent efficacy of ampicillin treatment.
Survival curves show one representative experiment, with 5 larvae per group. Groups of non-infected larvae received injections of PBS or
ampicillin (2mg/mL, 1mg/mL, 0.1mg/mL or 0.01mg/mL) were used as a negative control, and all survived until the endpoint of the
experiment. Only the control group injected with 2mg/mL ampicillin is shown on the graph.
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that survival increase in a dose-dependent manner
(Figure 4(D), additional replicate in Figure S3).
Discussion
In recent years, the use of Galleria mellonella larvae as
bacterial infection model has been developed as an
alternative to murine or other vertebrate models of
infection to contribute to the 3Rs (reduction, replace-
ment, and refinement) of animal use in scientific
research. In this work, we demonstrate the utility of
G. mellonella larvae as a GBS infection model. Unlike
previously evaluated Streptococcus species, which are
predominantly associated with a single host species,
GBS is a multi-host pathogen, and we provide, to our
knowledge, the first comparison of virulence in this
model for Streptococcus isolates obtained from clinical
disease across multiple host species. GBS disease iso-
lates are able to establish systemic infection of
G. mellonella larvae with extensive bacterial replica-
tion and dose-dependent larval survival. The model is
broadly applicable, with GBS isolates from multiple
hosts, encompassing both homeothermic and poiki-
lothermic species, able to establish a lethal infection.
Unlike other invertebrate models such as
Caenorhabditis elegans and Drosophila melanogaster,
G. mellonella larvae are able to survive at 37°C and 28°
C, enabling the study of GBS infection in the range of
relevant host-specific temperatures [58].
Other in vivo models of GBS infection exist, includ-
ing models that have been used for comparison of
isolates from different host species, e.g. human and
bovine isolates in a bovine mammary gland challenge
or human, bovine and piscine isolates in a tilapia chal-
lenge model [31,59]. Major drawbacks of such models
are the fact that they can only be used at a temperature
that is appropriate for the homeothermic or poiki-
lothermic host species used, and that they fail to reduce
the use of vertebrate animals in research. Use of
Galleria overcomes both limitations, although the
model has limitations of its own. For example, GBS
virulence in bovines is associated with the presence of
the lactose metabolism operon Lac.2, which is largely
absent from non-bovine isolates. The utilization of
lactose (milk sugar) by GBS bovine strains facilitates
bacterial survival and infection in milk-producing
mammary glands but would not confer a survival
advantage in other tissues [60,61]. This is reflected in
lack of a significant difference in virulence of human
and bovine isolates in our model. Conversely, a mobile
genetic element that encodes galactose metabolism is
thought to be associated with GBS virulence in fishes,
regardless of ST, yet the Galleria model shows that
ST283 is more virulent than other fish-associated
strains [38]. Recently, the use of a clinical ST283
human isolate in a murine model showed a clear
increase in virulence compared to that of a clinical
ST23 human isolate [62], but the basis for the hyper-
virulence of this ST remains largely unknown. The
hypervirulence of ST283 strains in the Galleria model
raises the possibility of utilizing this cost-effective
model to screen transposon or other mutant libraries
to identify key GBS virulence factors specific to this
sequence type. Likewise, the hyper-virulent ST17 iso-
lates showed a slight increase in virulence compared to
homeothermic non-ST17 strains, suggesting that at
least some specific virulence factors are reflected in
the G. mellonella larvae model. Testing the virulence
of deletion mutants of known ST17-specific virulence
factors, such as HvgA, would provide more information
on the model’s utility for study of mechanism contri-
buting to GBS virulence in humans.
Due to the importance of GBS as a human, live-
stock and aquaculture pathogen and the widespread
use of antibiotics to prevent or treat GBS infections,
there is a pressing need to identify and develop new
anti-GBS strategies that could limit the associated
spread of antimicrobial resistance. In this respect,
invertebrate infection models are very attractive for
the screening of new antimicrobials, to compare their
efficacy to known antibiotics, or study the effect of
antibiotic combinations [35,49,63,64]. To demonstrate
the potential to use G. mellonella larvae for in vivo
screening of antimicrobials we show that known anti-
biotics are able to afford protection against a lethal
GBS infection. Indeed, the systemic injection of com-
monly used anti-GBS antibiotics, such as erythromy-
cin, ampicillin or tetracycline, in the hemolymph of
infected larvae is able to rescue those infected with
susceptible strains but not those infected with resistant
strains. This model could, therefore, be used as
a bridge between in vitro studies and the more rele-
vant and costly animal models, such as rodents for
human isolates or cattle for bovine isolates, to test the
efficacy of novel antimicrobials compounds. However,
while the G. mellonella larvae model is useful to test
the efficacy of antimicrobials compounds such as anti-
biotics, the lack of adaptive immune system renders it
useless for the screening of potential vaccines.
Overall, we show that the G. mellonella larvae model
can be used as an infectionmodel for GBS isolates from all
host species and reflects the hypervirulence of ST283 and
ST17, both of which are associated with invasive disease in
humans. Furthermore, we show that this model can be
used as a bridge between in vitro and in vivo studies for
the screening of antimicrobial compounds.
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Materials and methods
Bacteria and growth conditions
GBS isolates used in this study are described in Table
S1. The panel of isolates represents a range of capsular
serotypes and STs found in the three major host cate-
gories (human, bovine and fish). All human isolates
originated from urinary tract infections so that poten-
tial differences in virulence between isolates within
a host species could be associated with ST or serotype
rather than clinical origin. Similarly, all bovine isolates
originated from the milk of animals with mastitis.
Where possible, human and bovine isolates of each
ST were included to allow for assessment of host effects
within ST. For fish isolates, the range of available STs
was limited and represented the major CCs and sero-
types known to be associated with naturally occurring
infection in fishes (ST7-serotype Ia; ST283-serotype III;
CC552-serotype Ib) [19]. GBS was stored at −80°C in
25% (v/v) glycerol and cultured in Brain Heart Infusion
broth/agar medium (BHI, Oxoid) at 37°C, with the
exception of ST260, a member of the poikilothermic
CC552, which were grown at their optimal temperature
of growth, 28°C with the media and conditions used.
Galleria mellonella challenge
G. mellonella larvae were obtained from Livefood UK.
They were kept in darkness at room temperature and
were used maximum one week following arrival.
Healthy larvae measuring from 2 to 2.5 cm in length
and showing no signs of melanization were used for all
experiments. GBS isolates were grown in BHI at 37°C
or 28°C to an OD600 = 0.4–0.6. Cells were then washed
twice in sterile PBS and diluted to the desired inoculum
in PBS. Inoculums were serially diluted and plated on
BHI agar plates just before administration for CFU
counting. For the determination of the LD50 of GBS
isolates, 4 groups of 10 larvae were injected with 10 µL
of serial dilutions of bacterial suspension in the hemo-
coel via the last right pro-limb. Following challenge,
larvae were placed in an incubator at 37°C or at 28°C
in the case of ST260 isolates. Survival was followed for
48 h, larvae were considered dead when non-responsive
to touch. LD50 was calculated using the Probit method
(XLSTAT software). Survival curves were plotted using
the Kaplan–Meier method and differences in survival
were calculated using the log-rank test (GraphPad
Prism 6). Experiments were done at least twice. One
representative experiment is shown in the main text for
survival curves, with additional data shown in the
Supplementary material. Differences in LD50 between
strains defined based on host, ST or serotype were
assessed using Mann–Whitney test. To assess antibiotic
efficiency, larvae were challenged with the LD90 of the
GBS isolate tested and injected 2 h postinfection with
10 µL of 2 mg/mL erythromycin (Duchefa Biochemie),
ampicillin (Melford Biolaboratories Ltd) or tetracycline
(Sigma) in the hemocoel via the last left pro-limb. For
all challenge experiments, a sham-inoculation of PBS
was used for uninfected control larvae (n = 10 per
experiment unless stated otherwise) to account for
mortality caused by physical injury or infection by
a contaminant. All larvae inoculated with PBS survived.
Differences in survival rates between treated and
untreated larvae were assessed using one-way
ANOVA test followed by Dunnett test.
To assess the dose–response of ampicillin, groups of
5 larvae were challenged with a lethal dose of ST283
fish isolate STIR-CD-25 and injected 2 hpost infection
with 10 µL of ampicillin at 2.0, 1.0, 0.10 or 0.010 mg/
mL. Experiments were performed 3 times and sham-
inoculation of PBS or ampicillin was used for unin-
fected control larvae. Dose-dependent survival was
observed with increasing ampicillin concentration
(Figure 4(D), with replicate shown in Figure S3).
In vivo GBS growth curve
For the in vivo growth curve experiment, larvae were
challenged with 106 CFU of GBS. At each time point,
groups of 3 larvae were kept at −20°C for 10 min before
being transferred to Eppendorfs containing 100 µL of
sterile PBS, homogenized, serially diluted and plated on
chromogenic selective GBS Brilliance agar for quantifi-
cation (Thermo Scientific, Basingstoke UK; PO5320A).
Homogenization was performed using FastPrep lysing
matrix M (MPbio).
Immunohistochemistry (IHC) and histological
analysis
Larvae were challenged with 106 CFU of a fish-derived
ST283 isolate (MRI Z2-366). Uninfected and infected
larvae were collected immediately after inoculation, and
6 h and 12 h postchallenge and kept at −20°C for up to 10
min before fixation. Whole larvae were placed in 10⨰
volume of 10% neutral buffer formalin at room tempera-
ture for 48 h. Longitudinal and cross sections of paraffin-
embedded larvae were prepared to detect GBS presence in
an early, middle and late phase of challenge. For antigen
retrieval, heat-induced epitope retrieval (HIER) was car-
ried out using a Menarini Access Retrieval Unit (Biocare
LLC, California, USA), in 10 mM Sodium Citrate buffer,
pH 6.0 for 1 min 40 sat 125°C full pressure. Slides were
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loaded on to Dako Autostainer (Dako Colorado, INC.,
Colorado, USA) and rinsed 5 min with a Tris-buffered
saline solution (TBS), pH 7.6 containing 0.05% Tween 20.
Endogenous peroxidase was blocked with Dako REAL™
Peroxidase-Blocking Solution (S2023) for 5 min and then
rinsed with buffer. Slides were incubated 30 min at room
temperature with anti-Streptococcus group B antibody
ab53584 (Abcam, Cambridge, UK) diluted 1: 200 in
Dako universal diluent (S2022), washed, and then further
incubated with anti-rabbit horseradish-peroxidase-
labeled polymer (Dako, K5007ENV) for 30 min at room
temperature. After incubation with 3,3ʹ-
diaminobenzidine (5 min, RT; Dako, K5007 DAB), the
slides were rinsed three times with hydrogen peroxide and
counterstained with Gills Haematoxylin for 27 s. Pictures
were acquired on EVOS Fl Auto 2 Imaging System
(Invitrogen).
Antibiotics
The minimum inhibitory concentration (MIC) was eval-
uated using the broth dilution technique for strains used
in the assessment of antibiotic efficiency. Microdilution
plates containing 200 µL BHI broth medium (Oxoid)
with decreasing concentration of antibiotics (erythromy-
cin, Duchefa Biochemie; ampicillin, Melford
Biolaboratories Ltd; tetracycline, Sigma; 256–0.125 µg/
mL) were inoculated from overnight cultures. After over-
night incubation, cultures were checked for growth, with
the MIC being the lowest concentration of antibiotics
that prevents visible growth.
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